JOURNAL OF CLINICAL RESEARCH BEST PRACTICES
Vol. 9, No. 11, November 2013 "Happy Trials to You"

"PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2013/2014"

Mark P. Mathieu, editor, 2013, 416 pages, PAREXEL International, $425.00

Review by Norman M. Goldfarb

"PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2013/2014" is the industry's most complete compendium of statistics and other facts about drug development. The book includes hundreds of charts, tables, figures and analyses in five sections:

- R&D Spending
- Products in Development
- Drug Development Costs/Complexity, Development Time, and Success Rates
- Regulatory/FDA Statistics
- International Statistics

A few of the fascinating findings in the book include the following:

- Global R&D spending by PhRMA members has been basically flat since 2007.
- The majority of top-100 drugs will be biologics (large molecules) by 2018.
- Thirteen of the top 20 drugs in 2011 (and all of the top six) will be off-patent by 2016.
- Depending on who you ask, 12 to 16 biopharmaceutical companies have over 100 new products in development. The total exceeds 10,000.
- The portion of procedure costs that are standard of care ranges from 26% in CNS studies to 39% in musculoskeletal system and connective tissue studies.
- Fifty-one percent of U.S. site study budgets include a start-up fee, in contrast to 19% in Eastern Europe and Latin America.
- The median screen failure rate is 34% in Phase II studies and 25% in Phase III studies.
- The average study monitor in North America spends 10 days per month at sites.
- On average, the period from pre-study visit to site initiation ranges from 5.6 months in North America to 14.1 months in Latin America.

The book is available at www.barnettinternational.com.

Reviewer

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Contact him at 1.650.465.0119 or ngoldfarb@firstclinical.com.